| Company/Division name | Continuus Pharmaceuticals |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2023 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 69.3 |
| City reshored to: | Woburn |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | generic medications |
| What non-domestic negative factors made offshoring less attractive? | Quality/rework/warranty, Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Customer responsiveness improvement, Government Incentives, Lead time/Time to market, Proximity to customers/market, Skilled workforce availability/training, covid-19 |
| Government Incentive dollar amount: | $69.3 million DoD, HHS contract |
